Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INTUITIVE SURGICAL, INC.

(ISRG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
348.65(c) 340.72(c) 335.9(c) 339.42(c) 329.23(c) Last
1 680 834 2 041 454 2 072 368 993 529 1 491 728 Volume
-2.94% -2.27% -1.41% +1.05% -3.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 5 676 M - -
Net income 2021 1 661 M - -
Net cash position 2021 2 642 M - -
P/E ratio 2021 73,9x
Yield 2021 -
Sales 2022 6 409 M - -
Net income 2022 1 718 M - -
Net cash position 2022 4 987 M - -
P/E ratio 2022 71,2x
Yield 2022 -
Capitalization 118 B 118 B -
EV / Sales 2021 20,3x
EV / Sales 2022 17,6x
Nbr of Employees 8 081
Free-Float 99,0%
More Financials
Company
Intuitive Surgical, Inc. develops, manufactures and markets the da Vinci surgical system and Ion endoluminal system. The Company's da Vinci products are offered in categories, including da Vinci Surgical Systems, da Vinci instruments and accessories, da Vinci Stapling, da Vinci Energy, and da Vinci Vision, including Firefly Fluorescence imaging systems (Firefly) and da Vinci Endoscopes. It also provides a... 
More about the company
Ratings of Intuitive Surgical, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about INTUITIVE SURGICAL, INC.
11/22Intuitive Announces Executive Leadership Changes
AQ
10/21INTUITIVE SURGICAL : Morgan Stanley Adjusts Price Target on Intuitive Surgical to $325 fro..
MT
10/20INTUITIVE SURGICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
10/20Tranche Update on Intuitive Surgical, Inc.'s Equity Buyback Plan announced on February ..
CI
10/20INTUITIVE SURGICAL : Wells Fargo Adjusts Intuitive Surgical's Price Target to $381 from $3..
MT
10/20INTUITIVE SURGICAL : UBS Adjusts Price Target on Intuitive Surgical to $352 From $323 on I..
MT
10/20INTUITIVE SURGICAL : Deutsche Bank Adjusts Intuitive Surgical PT to $323 From $306, Mainta..
MT
10/19Intuitive Surgical 3Q Beats Analyst Views
DJ
10/19Intuitive Surgical Names Executives for Strategy and Growth, Global Business Services
DJ
10/19INTUITIVE SURGICAL : Q3 Non-GAAP Earnings, Revenue Rise From Last Year
MT
10/19INTUITIVE SURGICAL : Names Jamie Samath as CFO, Dave Rosa as Chief Strategy & Growth Offic..
MT
10/19INTUITIVE SURGICAL : ANNOUNCES THIRD QUARTER EARNINGS - Form 8-K
PU
10/19INTUITIVE SURGICAL INC : Results of Operations and Financial Condition (form 8-K)
AQ
10/19Intuitive Surgical, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
10/19INTUITIVE SURGICAL : Earnings Flash (ISRG) INTUITIVE SURGICAL Reports Q3 Revenue $1.4B
MT
More news
News in other languages on INTUITIVE SURGICAL, INC.
11/22BÖRSE STUTTGART-NEWS : Euwax Trends
11/02BÖRSE STUTTGART-NEWS : Euwax Trends
10/19Le bénéfice non GAAP et le revenu d'Intuitive Surgical au troisième trimestre sont en h..
10/19Intuitive Surgical nomme Jamie Samath au poste de directeur financier et Dave Rosa au p..
10/19Earnings Flash (ISRG) INTUITIVE SURGICAL annonce un chiffre d'affaires de 1,4 milliard ..
More news
Analyst Recommendations on INTUITIVE SURGICAL, INC.
More recommendations
Stock Trading Strategies
INTUITIVE SURGICAL, INC. - 10/11
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart INTUITIVE SURGICAL, INC.
Duration : Period :
Intuitive Surgical, Inc. Technical Analysis Chart | ISRG | US46120E6023 | MarketScreener
Technical analysis trends INTUITIVE SURGICAL, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 329,23 $
Average target price 348,50 $
Spread / Average Target 5,85%
EPS Revisions
Managers and Directors
Gary S. Guthart President, Chief Executive Officer & Director
Marshall L. Mohr Chief Financial Officer & Executive Vice President
Calvin Darling Senior Director-Finance & Investor Relations
Craig H. Barratt Chairman
Myriam J. Curet Chief Medical Officer & Executive Vice President
Sector and Competitors